Published in Blood Transfus on September 01, 2013
Plasma and plasma-derived medicinal product self-sufficiency: the Italian case. Blood Transfus (2013) 1.64
Plasma-derived medicinal products: demand and clinical use. Blood Transfus (2013) 0.75
How we treat bleeding associated with direct oral anticoagulants. Blood Transfus (2016) 0.75
Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol (2011) 4.98
2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg (2011) 4.84
Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol (2013) 4.04
Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care (2013) 3.65
Guidelines on oral anticoagulation (warfarin): third edition--2005 update. Br J Haematol (2006) 3.03
An update of consensus guidelines for warfarin reversal. Med J Aust (2013) 2.41
Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol (2008) 2.27
The rare coagulation disorders--review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia (2004) 1.92
Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol (2012) 1.80
Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost (2004) 1.69
Plasma-derived medicinal products in Italy: information sources and flows. Blood Transfus (2013) 1.63
Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity. Crit Care (2011) 1.40
Prothrombin complex concentrates: an update. Blood Transfus (2010) 1.27
Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". Blood Transfus (2013) 1.23
Anticoagulants and their reversal. Transfus Med Rev (2007) 1.18
French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res (2010) 1.17
Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost (2006) 1.11
Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus (2009) 1.05
Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage. Eur J Gastroenterol Hepatol (2003) 0.98
Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia (2000) 0.97
Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res (1999) 0.92
Prothrombin complex concentrates in emergency bleeding disorders. Am J Hematol (2012) 0.87
Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res (1999) 0.86
Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe haemorrhage - from theory to practice. Crit Care (2009) 0.86
Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica (2006) 0.85
Perioperative management of coagulation in nontraumatic intracerebral hemorrhage. Anesthesiology (2013) 0.81
The evolution of the regulatory framework for the plasma and plasma-derived medicinal products system in Italy. Blood Transfus (2013) 2.29
Plasma and plasma-derived medicinal product self-sufficiency: the Italian case. Blood Transfus (2013) 1.64
Plasma-derived medicinal products in Italy: information sources and flows. Blood Transfus (2013) 1.63
Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus (2014) 1.46
Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfus (2015) 1.46
Zika virus and the never-ending story of emerging pathogens and Transfusion Medicine. Blood Transfus (2015) 1.30
The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Transfus (2013) 1.05
Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates. Blood Transfus (2013) 0.99
Clinical use and the Italian demand for antithrombin. Blood Transfus (2013) 0.96
Leucoreduction of blood components: an effective way to increase blood safety? Blood Transfus (2015) 0.94
Public expenditure for plasma-derived and recombinant medicinal products in Italy. Blood Transfus (2013) 0.92
Intravenous iron and safety: is the end of the debate on the horizon? Blood Transfus (2014) 0.84
The demand for human albumin in Italy. Blood Transfus (2013) 0.83
Present and future challanges in the treatment of haemophilia: a clinician's perspective. Blood Transfus (2013) 0.83
The demand for polyvalent immunoglobulins in Italy. Blood Transfus (2013) 0.82
Blood donor selection in European Union directives: room for improvement. Blood Transfus (2015) 0.82
Present and future challenges in the treatment of haemophilia: the patient's perspective. Blood Transfus (2013) 0.82
Classic and alternative red blood cell storage strategies: seven years of "-omics" investigations. Blood Transfus (2014) 0.81
Hepatitis E: an old infection with new implications. Blood Transfus (2014) 0.80
Clinical use of factor VIII and factor IX concentrates. Blood Transfus (2013) 0.80
The 2013 update of the "Seville Document": a Spanish multidisciplinary alliance for patient blood management. Blood Transfus (2013) 0.79
Recombinant factor VIIa as haemostatic therapy in advanced liver disease. Blood Transfus (2012) 0.79
Italian albumin usage (or misusage?). Eur J Intern Med (2013) 0.76
Human Parvovirus B19 and blood product safety: a tale of twenty years of improvements. Blood Transfus (2015) 0.76
Multicentre standardisation of a clinical grade procedure for the preparation of allogeneic platelet concentrates from umbilical cord blood. Blood Transfus (2015) 0.75
Convalescent plasma: new evidence for an old therapeutic tool? Blood Transfus (2015) 0.75
Plasma-derived medicinal products: demand and clinical use. Blood Transfus (2013) 0.75
Learn more to do better... even for participants in haemophilia clinical trials. Blood Transfus (2015) 0.75
Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use. Blood Transfus (2016) 0.75
Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfus (2015) 0.75
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: a multicenter retrospective cohort study. Haematologica (2015) 0.75
Haemophilia B is clinically less severe than haemophilia A: further evidence. Blood Transfus (2016) 0.75
The increased demand for plasma-derived factor VIII in Italy. Blood Transfus (2016) 0.75
Recommendations for factor VIII product source to treat patients with haemophilia A. Blood Transfus (2017) 0.75